2223 completed, 184 terminated, 88 recruiting, 55 active not recruiting. 1119 Phase 1, 461 Phase 3, 409 Phase 2, 192 Phase 4, 58 Not applicable.
Follow Boehringer Ingelheim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction Jardiance, non-SGLT2 inhibitors - Heart Failure of Reduced Ejection Fraction (HFrEF) | Not yet recruiting | Boehringer Ingelheim | 5000 | 2028-01-31 | 2026-09-15 | |
| Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction Heart Failure, Preserved Ejection Fraction | Not yet recruiting | Boehringer Ingelheim | 3000 | 2028-01-31 | 2026-09-16 | |
| A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers BI 1831169, nivolumab - Solid Tumors | Phase 1 | Suspended | Boehringer Ingelheim | 46 | 2027-08-03 | 2026-07-07 |
| A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-04-01 | 2026-10-28 |
| The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease Verducatib, Placebo matching verducatib - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 1800 | 2027-03-10 | 2026-10-30 |
| A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies Placebo, Nerandomilast - Idiopathic Inflammatory Myopathies | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 270 | 2026-12-14 | 2026-10-29 |
| SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Survodutide - Obesity | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 350 | 2026-11-07 | 2026-10-27 |
| A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People BI 3821001, Placebo - Healthy | Phase 1 | Not yet recruiting | Boehringer Ingelheim | 40 | 2026-11-03 | 2026-10-30 |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease Survodutide, Placebo matching survodutide - Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 600 | 2026-11-02 | 2026-10-30 |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Survodutide, Placebo - Obesity | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 600 | 2026-10-31 | 2026-10-30 |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-28 | 2026-10-27 |
| A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer BI 3968621, ezabenlimab - Advanced Solid Tumour | Phase 1 | Recruiting | Boehringer Ingelheim | 90 | 2026-10-26 | 2026-10-28 |
| A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 36 | 2026-10-14 | 2026-10-29 |
| A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours) BI 4060107 - Solid Tumours | Phase 1 | Recruiting | AIMEDBIO | 86 | 2026-10-09 | 2026-10-28 |
| A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways BI3034701 formulation II, BI3034701 formulation C1 - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 30 | 2026-10-05 | 2026-10-19 |
| A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 25 | 2026-10-04 | 2026-06-01 |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 55 | 2026-10-01 | 2026-10-13 |
| Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools EHR-Embedded CDS and PRO Tools Intervention - Rheumatoid Arthritis (RA), SSc-Systemic Sclerosis | Not applicable | Not yet recruiting | Foundation for Advancing Science Technology Education and Research | 800 | 2026-09-30 | 2026-09-30 |
| A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) BI 3822971 - Solid Tumours | Phase 1 | Recruiting | Boehringer Ingelheim | 137 | 2026-09-21 | 2026-10-27 |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression Nerandomilast, Placebo matching nerandomilast - Interstitial Lung Diseases | Phase 3 | Recruiting | Boehringer Ingelheim | 466 | 2026-09-17 | 2026-10-28 |
Showing 20 of 2675. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (276) · Diabetes Mellitus, Type 2 (153) · Hypertension (127) · Carcinoma, Non-Small-Cell Lung (89) · HIV Infections (80) · Atrial Fibrillation (71) · Asthma (67) · Neoplasms (67) · Idiopathic Pulmonary Fibrosis (53) · Parkinson Disease (46) · Lung Diseases, Interstitial (38) · Obesity (34) · Psoriasis (33) · Stroke (29) · Heart Failure (27)
empagliflozin (153) · Tiotropium Bromide (137) · Telmisartan (122) · Afatinib (116) · nintedanib (115) · Linagliptin (94) · Dabigatran (93) · olodaterol (62) · Ritonavir (60) · Pramipexole (50) · Metformin (49) · tipranavir (47) · Nevirapine (46) · Duloxetine Hydrochloride (38) · faldaprevir (34)
Germany (811) · United States (673) · Spain (335) · Canada (320) · France (319) · Japan (309) · United Kingdom (299) · Belgium (298) · Netherlands (284) · Italy (254) · South Korea (233) · Poland (187) · China (185) · Australia (182) · Austria (170)
Jeffrey Testani, MD (4) · Mireia Canals, +34607550925 (4) · Arlene Chapman, M.D. (2) · Arthur F Gelb, MD (2) · Christian Keicher, Dr. med. (2) · George Simon, MD (2)
PMID 35472672, PMID 32943047, PMID 38770818, PMID 31319851, PMID 39175217, PMID 22234149, PMID 31054118, PMID 36472162, PMID 31667790, PMID 24081972, PMID 33902584, PMID 36451029, PMID 36919398, PMID 21102344, PMID 23940010, PMID 25496316, PMID 27316632, PMID 29174062, PMID 30077810, PMID 31081589, PMID 32180164, PMID 32462607, PMID 32671684, PMID 32848381, PMID 34473343, PMID 34921669, PMID 37185961, PMID 38682786, PMID 40455255, PMID 22249355, PMID 22709460, PMID 23497760, PMID 24169807, PMID 24576516, PMID 25589191, PMID 26051236, PMID 27484756, PMID 27807306, PMID 28230262, PMID 28388260, PMID 28753486, PMID 29653649, PMID 29653820, PMID 30261995, PMID 30908082, PMID 31914963, PMID 32217654, PMID 32363771, PMID 32776202, PMID 33141449
2023 (55), 2009 (52), 2015 (47), 2017 (45), 2018 (45), 2008 (43), 2014 (39), 2019 (38), 2016 (35), 2025 (35), 2005 (7), 2004 (2), P30CA016056 (2), U01DK062401 (2), U01DK082230 (2)